Natum CG
Pediatric Health
Main benefits
It may promote intestinal health and immune maturation in newborns and infants, supporting infant-type intestinal colonization and reducing the risk of infections and complications in the pediatric population, including premature infants.
Evidence
Clinical studies in neonates and premature infants demonstrate good tolerance and an absence of serious adverse events. Meta-analyses show a reduction in NEC and mortality in premature infants with probiotic use, with favorable results in strains including Bifidobacterium breve M-16V.
Format
Oral powder (indicated for hospital administration).
Main attributes
• Strain: Bifidobacterium breve ...
• Dosage: 1 x 10⁹ CFU/day
• Safe even in newborns and premature infants
• Improves intestinal colonization and the proportion of Bifidobacterium
• Decreases the incidence of necrotizing enterocolitis and sepsis
• Supports intestinal metabolic function and the production of short-chain fatty acids
• Approved by the FDA (GRAS), EFSA, and ANVISA
• Can be combined with vitamin D3 and medium-chain triglycerides (MCTs)